Use of surrogate end points for prostate cancer-related mortality in clinical trials

被引：0

|

作者：

不详

机构：

来源：

Nature Clinical Practice Oncology | 2009年 / 6卷 / 2期

关键词：

D O I：

10.1038/ncponc1292

中图分类号：

学科分类号：

摘要：

[No abstract available]

引用

收藏

页码：61 / 62

页数：1

相关论文

共 50 条

[1] The Use of Modified Surrogate End Points in Cancer Clinical Trials
Al Hadidi, Samer
[J]. CANCER INVESTIGATION, 2022, 40 (01) : 14 - 16
[2] On the use of surrogate end points in randomized trials
Begg, CB
Leung, DHY
[J]. JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-STATISTICS IN SOCIETY, 2000, 163 : 15 - 24
[3] THE SCOPE OF NUTRITION INTERVENTION TRIALS WITH CANCER-RELATED END-POINTS
CHLEBOWSKI, RT
GROSVENOR, M
[J]. CANCER, 1994, 74 (09) : 2734 - 2738
[4] Validity of Surrogate End Points for Prostate Cancer
Baker, Stuart G.
[J]. JAMA ONCOLOGY, 2018, 4 (01) : 129 - 130
[5] On the use of surrogate end points in randomized trials - Comments
Prentice, RL
[J]. JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-STATISTICS IN SOCIETY, 2000, 163 : 26 - 27
[6] Surrogate End Points and Their Validation in Oncology Clinical Trials
Zhao, Fengmin
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (13) : 1436 - +
[7] Some statistical issues in the design of cancer clinical trials with surrogate end points
Piantadosi, S
[J]. ARCHIVES OF NEUROLOGY, 2000, 57 (08) : 1233 - 1233
[8] Surrogate end points in early prostate cancer clinical states: ready for implementation?
Kyriakopoulos, Christos E.
Antonarakis, Emmanuel S.
[J]. ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (24)
[9] Validity of Surrogate End Points for Prostate Cancer Reply
Royce, Trevor J.
Chen, Ming-Hui
D'Amico, Anthony V.
[J]. JAMA ONCOLOGY, 2018, 4 (01) : 130 - 131
[10] Biomarkers and surrogate end points in clinical trials of tuberculosis treatment
Davies, Geraint Rhys
Phillips, Patrick P. J.
Nunn, Andrew J.
[J]. JOURNAL OF INFECTIOUS DISEASES, 2007, 196 (04): : 648 - 649

← 1 2 3 4 5 →